Work

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

Year: 1999

Type: article

Study design: Clinical Trial

Source: Urology

DOI: 10.1016/s0090-4295(98)00539-1

Authors: Martin G. Sanda, David C. Smith, Linda G. Charles, Clara Hwang, Kenneth J. Pienta, Jeff Schlom, Diane Milenic, Dennis Panicali, James E. Montie

Institutions: University of Michigan, Michigan Medicine, Ann Arbor VA Medical Center, U-M Rogel Cancer Center, National Institutes of Health, National Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, National Cancer Institute, National Center for Research Resources

Awards: G1682948662, PROSTATE CANCER GENE THERAPY WITH RECOMBINANT VACCINES, G57319417, SPORE in Prostate Cancer, General Clinical Research Center, G8784434535

OpenAlex ID: W2067910064

FWCI: 15.7

Cites: 16

Cited by: 201

Related to: 10